Vertex Pharmaceuticals Inc (VRTX)

Interest coverage

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands -232,900 -270,400 -348,600 4,192,500 3,832,000 3,877,000 3,965,600 4,045,500 4,307,400 4,151,600 4,079,400 2,935,200 2,782,100 2,809,311 2,514,538 3,391,079 3,174,949 2,961,237 2,286,724 1,790,058
Interest expense (ttm) US$ in thousands 30,600 38,400 41,800 43,100 44,100 45,100 47,900 51,300 54,800 58,300 59,855 60,733 61,511 62,699 61,300 59,693 58,151 56,112 56,804 57,770
Interest coverage -7.61 -7.04 -8.34 97.27 86.89 85.96 82.79 78.86 78.60 71.21 68.15 48.33 45.23 44.81 41.02 56.81 54.60 52.77 40.26 30.99

December 31, 2024 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $-232,900K ÷ $30,600K
= -7.61

The interest coverage ratio indicates Vertex Pharmaceuticals Inc's ability to meet its interest obligations with its earnings before interest and taxes (EBIT). A higher interest coverage ratio is generally considered favorable as it suggests the company can easily cover its interest expenses.

Looking at the data provided, Vertex Pharmaceuticals Inc's interest coverage ratio has displayed some fluctuation over the periods. The ratio ranged from 30.99 in March 2020 to a peak of 97.27 in March 2024, which suggests a strong ability to cover interest payments with operating income during this period.

However, there were instances where the interest coverage ratio dropped below 1, specifically in June 2024, September 2024, and December 2024. This implies that in those particular quarters, Vertex Pharmaceuticals Inc may have had difficulty meeting its interest obligations with its earnings.

It is important to assess the reasons behind the significant decrease in the interest coverage ratio during those quarters to understand if it was due to temporary circumstances or if there are underlying issues that need to be addressed. Overall, while the company has shown a strong interest coverage ratio in many periods, attention should be paid to the quarters where the ratio fell below 1 to ensure the sustainability of the company's financial health.


See also:

Vertex Pharmaceuticals Inc Interest Coverage (Quarterly Data)